Toxic effects of nucleoside reverse transcriptase inhibitors on the liver: Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy

American Journal of Clinical Pathology

Volumn 119, Issue 4, 2003, Pages 546-555

  Duong Van Huyen, Jean Paul ^a,b   Landau, Alain ^a   Piketty, Christophe ^a,b   Bélair, Marie France ^b   Batisse, Dominique ^a   Gonzalez Canali, Gustavo ^a   Weiss, Laurence ^a,b   Jian, Raymond ^a   Kazatchkine, Michel D ^a,b   Bruneval, Patrick ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Electron microscopy; Liver biopsy; Mitochondrial toxicity; Nucleoside reverse transcriptase inhibitor

Indexed keywords

CARNITINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; LAMIVUDINE; MULTIVITAMIN; NEVIRAPINE; NICOTINAMIDE; PANTOTHENATE CALCIUM; PYRIDOXINE; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THIAMINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; FEMALE; FRANCE; HEPATITIS; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER NECROSIS; LIVER SINUSOID; LIVER TOXICITY; MALE; MALLORY BODY; MEGAMITOCHONDRION; PRIORITY JOURNAL; STEATOSIS; SYMPTOM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FATTY LIVER; LIVER; MIDDLE AGED; MITOCHONDRION; PATHOLOGY; ULTRASTRUCTURE;

ADULT; ANTI-HIV AGENTS; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; LIVER; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0038689517     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/8B8B-J6AP-5KGV-7C1H     Document Type: Article

References (33)

1. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335:1081-1090.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity: a challenge for the hepatologist? J Hepatol. 2002;36:283-294.
4. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185-194.
5. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
6. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1:417-422.
7. Lewis W, Gonzalez B, Chomyn A, et al. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest. 1992;89:1354-1360.
8. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med. 2000;133:192-196.
9. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 1999;30:156-160.
10. Bissuel F, Bruneel F, Habersetzer F, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med. 1994;235:367-371.
11. Olano JP, Borucki MJ, Wen JW, et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis. 1995;21:973-976.
12. Shaer AJ, Rastegar A. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome: a case report and review of the literature. Am J Nephrol. 2000;20:332-338.
13. Lai KK, Gang DL, Zawacki JK, et al. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann Intern Med. 1991;115:283-284.
14. Chattha G, Arieff AI, Cummings C, et al. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med. 1993;118:37-39.
15. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'épidemiologie Clinique du Sida en Aquitaine (GECSA). AIDS. 1999;13:F115-F121.
16. Fortgang IS, Belitsos PC, Chaisson RE, et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol. 1995;90:1433-1436.
17. Charton-Bain MC, Flamant M, Aubertin JM, et al. Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine. Gastroenterol Clin Biol. 1997;21:979-981.
18. Clark SJ, Creighton S, Portmann B, et al. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol. 2002;36:295-301.
19. Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir [letter]. Lancet. 1997;350:364.
20. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
21. Picard O, Rosmorduc O, Cabane J. Hepatotoxicity associated with ritonavir. Ann Intern Med. 1998;129:670-671.
22. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-166.
23. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest. 2001;81:777-790.
24. Gisolf EH, Dreezen C, Danner SA, et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis. 2000;31:1234-1239.
25. Lacaille F, Ortigao MB, Debre M, et al. Hepatic toxicity associated with 2′-3′dideoxyinosine in children with AIDS. J Pediatr Gastroenterol Nutr. 1995;20:287-290.
26. Hu B, French SW. 2′,3′-Dideoxyinosine-induced Mallory bodies in patients with HIV. Am J Clin Pathol. 1997;108:280-283.
27. Allory Y, Charlotte F, Benhamou Y, et al. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum Pathol. 2000;31:69-74.
28. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 1991;337:508-510.
29. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
30. Corcuera T, Alonso MJ, Picazo A, et al. Hepatic morphological alterations induced by zidovudine (ZDV) in an experimental model. Pathol Res Pract. 1996;192:182-187.
31. Shapiro SH, Klavins JV. Concentric membranous bodies and giant mitochondria in hepatocytes from a patient with AIDS. Ultrastruct PathoI. 1993;17:557-563.
32. Radovanovic J, Todorovic V, Boricic I, et al. Comparative ultrastructural studies on mitochondrial pathology in the liver of AIDS patients: clusters of mitochondria, protuberances, "minimitochondria, " vacuoles, and virus-like particles. Ultrastruct Pathol. 1999;23:19-24.
33. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.